Common injection sites include: Abdomen Thigh Upper arm Safety Considerations and Side Effects GLP-1 Safety Profile Common Side Effects: Gastrointestinal issues (nausea, vomiting, diarrhea) Reduced appetite Headache Fatigue Serious but Rare: Pancreatitis Gallbladder problems Kidney issues Thyroid tumors (in animal studies
Serna-Higuita LM, Isaza-Lpez MC, Hernndez-Herrera GN, et al
Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain, which are usually mild to moderate and diminish over time as the dose is gradually increased
Key risk factors include: Rapid weight loss: Losing weight quickly significantly increases gallstone risk Female sex: Women are two to three times more likely to develop gallstones than men Age over 40 years: Gallstone prevalence increases with age Obesity: Higher baseline BMI correlates with increased risk Previous history of gallstones: Prior biliary disease predicts recurrence Family history: Genetic factors contribute to gallstone susceptibility Certain ethnicities: Native American and Hispanic populations have higher baseline rates Estrogen exposure: Oral contraceptives, hormone replacement therapy, and multiple pregnancies Diabetes and dyslipidemia: Metabolic conditions affecting bile composition Prolonged fasting or TPN use: Reduces gallbladder contraction Patients should be educated about warning signs that may indicate gallstone complications
[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptortargeted therapy for insulinoma
